<style face="normal" font="default" size="100%">Intratumoral administration of CD1c (BDCA-1)<sup>+</sup> and CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial</style>

Drupal-HighWire